Parasite proteins targeted by the medicines for malaria ventures (MMV) malaria box: identification, functional and structural validation
Malaria is a mosquito-borne disease with huge global disease mortality and morbidity. Research and development of new anti-malarial drug development are essential in light of resistance to current first-line therapies. Here, we identified Plasmodium falciparum purine nucleoside phosphorylase as the...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Thesis-Doctor of Philosophy |
| Language: | English |
| Published: |
Nanyang Technological University
2024
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10356/181844 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Nanyang Technological University |
| Language: | English |
| Summary: | Malaria is a mosquito-borne disease with huge global disease mortality and morbidity. Research and development of new anti-malarial drug development are essential in light of resistance to current first-line therapies. Here, we identified Plasmodium falciparum purine nucleoside phosphorylase as the target of MMV000848. Through biochemical and structural validation, the Malaria Box compound MMV000848 is shown to bind and inhibit PfPNP activity without inhibiting the human orthologue. These findings allow for structural modifications and development of more potent PfPNP-specific analogues based on analysed enzyme-inhibitor interactions of newly presented and previously existing PNP inhibitors. |
|---|